At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABCL AbCellera Biologics
Market Closed 01-09 16:00:00 EST
4.37
+0.26
+6.33%
盘后4.54
+0.17+3.89%
19:57 EST
High4.51Low4.17Vol6.46M
Open4.19D1 Closing4.11Amplitude8.15%
Mkt Cap1.31BTradable Cap886.02MTotal Shares299.34M
T/O28.27MT/O Rate3.19%Tradable Shares202.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake
Reuters  ·  2025-12-20
AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires Live  ·  2025-12-19
Sector Update: Health Care Stocks Rise Late Afternoon
AbCellera Biologics Says Bruker to Pay $36 Million Upfront in Patent Litigation Settlement
MT Newswires Live  ·  2025-12-18
AbCellera Biologics Says Bruker to Pay $36 Million Upfront in Patent Litigation Settlement
BRIEF-Abcellera And Bruker Reach Global Settlement Of Patent Litigation
Reuters  ·  2025-12-18
BRIEF-Abcellera And Bruker Reach Global Settlement Of Patent Litigation
Abcellera Biologics Inc - Bruker to Pay Abcellera $36 Mln Upfront and Future Royalties
THOMSON REUTERS  ·  2025-12-18
Abcellera Biologics Inc - Bruker to Pay Abcellera $36 Mln Upfront and Future Royalties
Abcellera and Bruker Reach Global Settlement of Patent Litigation
THOMSON REUTERS  ·  2025-12-18
Abcellera and Bruker Reach Global Settlement of Patent Litigation
AbCellera to Present at J.P. Morgan Healthcare Conference
Reuters  ·  2025-12-09
AbCellera to Present at J.P. Morgan Healthcare Conference
Assessing AbCellera Biologics (ABCL) Valuation as It Shifts Toward Proprietary Clinical Assets and Phase 1 Trials
Simply Wall St.  ·  2025-12-06
Assessing AbCellera Biologics (ABCL) Valuation as It Shifts Toward Proprietary Clinical Assets and Phase 1 Trials
Director John S. Montalbano Reports Acquisition of AbCellera Biologics Common Shares
Reuters  ·  2025-11-27
Director John S. Montalbano Reports Acquisition of AbCellera Biologics Common Shares
Assessing AbCellera Biologics (NasdaqGS:ABCL) Valuation After New Facility Launch and Pipeline Progress
Simply Wall St.  ·  2025-11-26
Assessing AbCellera Biologics (NasdaqGS:ABCL) Valuation After New Facility Launch and Pipeline Progress
Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics
TIPRANKS  ·  2025-11-20
Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics
Prelude Therapeutics reports third quarter net loss of $19.7 million
Reuters  ·  2025-11-12
Prelude Therapeutics reports third quarter net loss of $19.7 million
Stock Track | AbCellera Biologics Plunges 7.20% Following Board Reshuffle and Q3 Earnings Call
Stock Track  ·  2025-11-11
Stock Track | AbCellera Biologics Plunges 7.20% Following Board Reshuffle and Q3 Earnings Call
AbCellera Biologics’ Earnings Call: Key Insights
TIPRANKS  ·  2025-11-11
AbCellera Biologics’ Earnings Call: Key Insights
Stock Track | AbCellera Biologics Soars 7.03% on Board Appointment and Clinical Progress
Stock Track  ·  2025-11-11
Stock Track | AbCellera Biologics Soars 7.03% on Board Appointment and Clinical Progress
AbCellera Appoints Stephen Quake to Board as Andrew Lo Resigns
Reuters  ·  2025-11-10
AbCellera Appoints Stephen Quake to Board as Andrew Lo Resigns
Abcellera Appoints DR. Stephen Quake to Its Board of Directors
THOMSON REUTERS  ·  2025-11-10
Abcellera Appoints DR. Stephen Quake to Its Board of Directors
Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Potential Undervaluation
Stock Track  ·  2025-11-10
Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Potential Undervaluation
Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Undervaluation
Stock Track  ·  2025-11-10
Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Undervaluation
AbCellera Biologics (NasdaqGS:ABCL): How Does the Latest Clinical Progress Impact Its Valuation?
Simply Wall St.  ·  2025-11-10
AbCellera Biologics (NasdaqGS:ABCL): How Does the Latest Clinical Progress Impact Its Valuation?

Introduction

Company Name.
AbCellera Biologics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Issue price:
--